{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:09:41Z","timestamp":1792739381907,"version":"4.5.0"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,5,25]],"date-time":"2005-05-25T00:00:00Z","timestamp":1116979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> Nucleic acid extraction still harbours the potential for improvements in automation and sensitivity of nucleic acid amplification technology (NAT) testing. This study evaluates the feasibility of a novel automated high\u2010volume extraction protocol for NAT minipool testing in a blood bank setting.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> The chemagic Viral DNA\/RNA Kit special for automated purification of viral nucleic acids from 9\u00b76\u00a0ml of plasma by using the chemagic Magnetic Separation Module I was investigated. Analytical sensitivity for hepatitis C virus (HCV), human immunodeficiency virus\u20101 (HIV\u20101), hepatitis B virus (HBV), hepatitis A virus (HAV) and parvovirus B19 (B19) was compared to our present manual procedure that involves virus enrichment by centrifugation.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Chemagic technology allows automation of the viral DNA\/RNA extraction process. Viral nucleic acids were bound directly to magnetic beads from 9\u00b76\u2010ml minipools. By combining the automated magnetic beads\u2010based extraction technology with our in\u2010house TaqMan polymerase chain reaction (PCR) assays, 95% detection limits were 280\u00a0IU\/ml for HCV, 4955\u00a0IU\/ml for HIV\u20101, 249\u00a0IU\/ml for HBV, 462\u00a0IU\/ml for HAV and 460\u00a0IU\/ml for B19, calculated for an individual donation in a pool of 96 donors. The detection limits of our present method were 460\u00a0IU\/ml for HCV, 879\u00a0IU\/ml for HIV\u20101, 90\u00a0IU\/ml for HBV, 203\u00a0IU\/ml for HAV and 314\u00a0IU\/ml for B19.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The 95% detection limits obtained by using the chemagic method were within the regulatory requirements for blood donor screening. The sensitivities detected for HCV, HBV, HAV and B19 were found to be in a range similar to that of the manual purification method. Sensitivity for HIV\u20101, however, was found to be inferior for the chemagic method in this study.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2005.00649.x","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T10:20:17Z","timestamp":1123150817000},"page":"71-76","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of an automated high\u2010volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment"],"prefix":"10.1111","volume":"89","author":[{"given":"M. K.","family":"Hourfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00177.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)06318-1"},{"key":"e_1_2_6_4_2","unstructured":"M\u00fcller\u2010SchulteD:Polyvinyl alcohol\u2010based magnetic polymer particles methods for their preparation and their use. European Patent EP 0 843 591 2001. Available from:http:\/\/www.depatisnet.de"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00129.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40060718.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.12.4302-4308.2001"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00416.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.2.210"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.3.615-619.1999"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2005.00649.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2005.00649.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T22:26:14Z","timestamp":1696890374000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2005.00649.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1423-0410.2005.00649.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2005.00649.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}